Chronic Thromboembolic Pulmonary Hypertension by Wittine, Lara M. & Auger, William R.





Lara M. Wittine, MD
William R. Auger, MD
*
Address
*Division of Pulmonary and Critical Care Medicine, University of California,
San Diego, 9300 Campus Point Drive, La Jolla, CA 92037, USA
Email: bauger@UCSD.edu
Published online: 12 March 2010
* The Author(s) 2010. This article is published with open access at Springerlink.com
Opinion statement
The pulmonary hypertension (PH) and right heart dysfunction that results from chronic
thromboembolic involvement of the pulmonary vascular bed is potentially curable with
surgical endarterectomy. Over the past several decades, growing clinical experience has
brought about increased recognition of this treatable form of PH. Moreover, advances
in cardiothoracic surgical techniques have given an increasing number of patients with
chronic thromboembolic PH (CTEPH) a surgical remedy with decreasing perioperative
morbidity and mortality risks. The availability of pulmonary hypertensive—specific
medical therapy for CTEPH patients with surgically inaccessible disease also has
been a positive therapeutic advance over the past several years. However, despite
this progress, chronic thromboembolic disease as a sequela of acute pulmonary
emboli continues to be underappreciated. Furthermore, even if CTEPH has been
appropriately diagnosed, misinterpretation of diagnostic information may lead to
the inappropriate exclusion of patients from surgical consideration. This may result in
the prescription of pulmonary hypertensive medical therapy in CTEPH patients with
potentially surgically correctable disease. This difficulty arises from a lack of objective
criteriaastowhatconstitutes surgical chronic thromboembolicdisease,which primarily is
a result of the variability in surgical experience in specialty centers in the United
States. Consequently, clinicians must be wary about using pulmonary hypertensive
medications in CTEPH patients. Before prescription, it is important to exclude
patients from surgical consideration by consulting a specialized center with expertise in
this discipline.
Introduction
Chronic thromboembolic residua may occur follow-
ing a single or recurrent episode of acute pulmonary
embolism. In patients with pulmonary embolism,
the mechanical obstruction of the pulmonary vascular
bed, along with the gradual development of a small
vessel vasculopathy in the unobstructed vascular bed,
may result in pulmonary hypertension (PH) [1•]. Esti-
mates of the incidence of chronic thromboembolic PH(CTEPH) after acute pulmonary embolism range from
0.5% to 3.8% [2, 3]. If unrecognized or left untreated,
progressive right ventricular dysfunction with the ulti-
mate development of right heart failure is the expected
outcome. Additional observations relevant to the diag-
nosis of CTEPH include the following: There appears
to be no age or gender bias for the diagnosis of
CTEPH; this disease has been observed in pediatric
patients [4]. A history of acute venous thromboembo-
lism is not present in approximately 30% of patients
presenting with CTEPH [1]. Factors that appear to pre-
dispose to the development of CTEPH include recur-
rent embolic events, elevated pulmonary pressures at
presentation of an acute pulmonary embolic event,
and greater than 50% occlusion of the pulmonary vas-
c u l a rb e da f t e ra“single” embolic occurrence [2, 5].
Thrombophilic states associated with CTEPH include
the presence of a lupus anticoagulant, elevated levels
of antiphospholipid antibodies, and elevated levels
of factor VIII [6]. Deficiencies of protein C, protein S,
and antithrombin III, or the presence of factor V Leiden
and factor II mutations, do not appear to be associated
with a higher risk of CTEPH.
The symptoms and signs of CTEPH are similar to
those of other forms of PH and depend on the severity
of the disease at presentation (Table 1). Exertional
dyspnea and/or an unexplained decline in functional
status are the most frequent presenting complaints.
With the development of a significant degree of right
ventricular dysfunction, symptoms such as exertional
presyncope and physical signs including peripheral
edema, jugular venous distention, and hepatomegaly
may become evident. A unique physical finding in
30% of patients with CTEPH is the presence of flow
bruits over the lung fields, a finding not encountered
in patients with small vessel variants of pulmonary
arterial hypertension (PAH).
Unlike other variants of PAH, CTEPH is potentially
amenable to surgical correction. Although vessel
obstructions with chronic thromboemboli may occur
at any level in the pulmonary arterial system, only
those involving the main, lobar, or segmental arteries
are amenable to surgical correction. Therefore, the pri-
mary purpose of the diagnostic evaluation is to quan-
tify the degree of PH and right heart dysfunction (ie,
right heart catheterization), to establish its etiology,
and to determine the proximal extent of disease
(Fig. 1)[ 7••].
The preferred therapy for appropriate patients
with CTEPH is surgical removal of the chronic
thromboembolic lesions within the proximal vessel
with the intent to restore normal cardiopulmonary
hemodynamics, improve functional status, and pos-
itively affect survivorship [8]. However, medical
therapies directed at treating PH have been investi-
gated and increasingly used in subcategories of
CTEPH patients [9, 10]: 1) patients deemed inoper-
able because of extensive distal precapillary vascul-
opathy not amenable to surgery or those who have
significant comorbidities that contraindicate surgery
[11]; 2) the 10% to 15% of patients who have resid-
ual PH following thromboendarterectomy surgery
[12]; and 3) patients with severe hemodynamic
compromise, as a bridge to surgery.
Table 1. Signs and symptoms of chronic thromboembolic pulmonary
hypertension
Exertional dyspnea
Fatigue and declining functional status
Exertional chest pain
Exertional presyncope or syncope
Lower extremity edema
Right ventricular lift







& The mainstay of therapy for patients with CTEPH is anticoagulation,
regardless of candidacy for surgical endarterectomy. Whether or not a
thrombophilic state has been identified, lifelong anticoagulation is
recommended [1, 7••]. The most commonly used anticoagulant is
warfarin, usually with an international normalized ratio (INR) goal
of 2.5 to 3.5. However, this INR target often is modified on an
individual basis, such as in patients with comorbidities necessitating
the use of medications that might increase bleeding risks (eg, aspirin
products), elderly patients (a lower INR target), and individuals with
an underlying thrombophilia (eg, those with an antiphospholipid
syndrome, in whom a higher INR target might be recommended).
The most common side effect of anticoagulation is an excessive
bleeding tendency. For patients with contraindications to warfarin
therapy, or those who have failed to adequately prevent thrombosis
with warfarin, an alternative anticoagulant regimen should be
administered. The use of low molecular weight heparins or factor
Figure 1. Diagnostic approach to chronic thromboembolic
pulmonary hypertension. MR—magnetic resonance; V/Q—
ventilation/perfusion. (Adapted from Hoeper et al. [7••];
with permission.)
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contraindicated during pregnancy, necessitating transition to a low
molecular weight heparin or another acceptable anticoagulant
regimen for postendarterectomy patients who choose and are
clinically able to become pregnant.
Pulmonary hypertension pharmacotherapy
& The histopathologic examination of distal arteries in CTEPH patients
reveals vascular changes similar to those in patients with primary or
idiopathic PAH [13]. The mechanism as to why proximal obstruction
might lead to precapillary arteriography is not known. However, this
observation, as well as the acknowledgment that PH in CTEPH
patients does not entirely result from mechanical obstruction of the
pulmonary vasculature, establishes a pathophysiologic context for
the use of pulmonary vasodilator therapy in this patient population.
& Pharmacologic therapy for CTEPH has focused on three main classes
of drugs currently prescribed for treating idiopathic PAH: endothelin
receptor antagonists (ERAs), cyclic guanosine monophosphate
(cGMP) phosphodiesterase 5 (PDE5) inhibitors, and prostanoids.
Several open-label studies of pharmacologic agents performed in
small patient groups suggest a role for medical therapy in those with
inoperable or residual postoperative CTEPH [14–19]. However, as
few well-designed placebo-controlled, randomized control trials
have been performed to evaluate the efficacy of drug treatment
in these patients, it is difficult to make a strong recommendation
regarding appropriate therapeutic choice.
& The BENEFiT (Bosentan Effects in Inoperable Forms of Chronic
Thromboembolic Pulmonary Hypertension) trial was a double-
blind, randomized, placebo-controlled study examining the use of
the ERA bosentan in patients with inoperable CTEPH or residual/
recurrent PH post endarterectomy. This study of 57 patients showed
improved pulmonary hemodynamics (pulmonary vascular resistance
[PVR] −24.1% of baseline) after 4 months of treatment with bosentan
[20••]. The hemodynamic change, however, did not render a signifi-
cant improvement inexercise capacity, and itis speculated that the trial
did not continue long enough to be able to evaluate for this end point
adequately. Sildenafil, a cGMP PDE5 inhibitor, also has been investi-
gated as a treatment for inoperable CTEPH. The one randomized,
placebo-controlled study of sildenafil use in patients with inoperable
CTEPH was too underpowered (N=19 enrolled patients) to prove
functional benefit, but the open-label portion of this study suggested
that prolonged (1-year) therapy with this medication may improve
PVR, exercise capacity, and symptom scores [21]. Although changes in
pulmonary hemodynamics have been seen to occur with short-term
administration(3–4months)ofbosentanandsildenafil,longerfollow-
up is needed to determine whether this will translate into improved
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from endarterectomy [20••, 21]. According to the recommendations
from the Fourth World Symposium on Pulmonary Hypertension for
CTEPHpatientswithinoperableorresidualpostoperativedisease,these
patients should be referred to medical centers experienced in treating
such patients for possible inclusion in clinical trials to investigate
pharmacologic treatments [7••].
& In CTEPH patients who are surgical candidates for thromboendar-
terectomy, a variety of pharmacologic agents, including bosentan,
prostacyclins, and iloprost, have been studied as a bridge to
pulmonary endarterectomy (PEA); however, overall, no significant
difference in postoperative hemodynamics was detected in patients
who received drug before endarterectomy compared with those
undergoing surgery alone [22, 23]. A large retrospective study con-
firmed these findings and raised the concern that patients receiving
drug therapy have delayed referral to surgery and increased medical
costs [10]. However, much of the impetus to affect pulmonary
hemodynamics before surgery comes from the observation that
CTEPH patients with preoperative PVR greater than 1,000
dynes·s·cm
−5 have a significantly higher perioperative mortality risk
[4]. An open-label study investigating continuous intravenous (IV)
prostacyclin in 12 patients with severe PH (PVR91200 dynes·s·cm
−5)
undergoing endarterectomy surgery demonstrated a significant reduc-
tion in preoperative PVR, with a trend toward improved operative
mortality [22]. Because no definitive evidence exists that pulmonary
vasodilator therapy positively affects outcomes in severe, hemodynam-
icallycompromisedsurgicalcandidates(PVR91000dynes·s·cm
−5),the
preoperative administration of prostanoids, ERAs, and/or PDE5 inhib-
itors in this patient group should be coordinated with a center special-
izing in the surgical management of CTEPH.
Endothelin receptor antagonists
Endothelin 1 is a potent vasoconstrictor that appears in higher levels in
patients with PH and affects the vasculature via endothelin receptors
A and B. ERAs block pulmonary vasoconstriction via one receptor
(selective) or both receptors (nonselective).
Bosentan, a nonselective ERA, is the most thoroughly and rigorously
studied to date of all pharmacologic therapies (via the BENEFiT trial) for
patients with inoperable CTEPH or post-PEA residual PH. Bosentan
improves cardiopulmonary hemodynamics, as evidenced by significant
decreases in PVR and significantly improved cardiac indices. Decreased
levels of pro-brain natriuretic peptide (pro-BNP) also suggest reduced
right ventricular strain [20••].
Standard dosage Bosentan: initial oral dose of 62.5 mg twice a day for 4 weeks, increasing to
target dose of 125 mg twice a day. Laboratory monitoring: monthly liver
function tests and complete blood count at 1 month, 3 months, then
quarterly. If applicable, pregnancy screening should be done monthly and if
there is an immediate concern about potential pregnancy [20••, 24].
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comitant administration of cyclosporine, glyburide, and lopinavir/
ritonavir [24].
Main drug interactions Contraindicated: cyclosporine and glyburide. Major interaction: ritonavir
[24].
Main side effects Mild liver function abnormalities (7–11%) to fulminant liver failure (rare),
peripheral edema (5–14%), palpitations (5%), flushing (7–14%), headache
(up to 24%), anemia (3–6%), and rhinitis (5%) [20••, 24].
Phosphodiesterase 5 inhibitors
PH is associated with upregulation of vascular PDE5, which rapidly
degrades cGMP, leading to reduced levels of nitric oxide, a potent
vasodilator. PDE5 inhibitors enhance nitric oxide-mediated vasodi-
lation. They also may have additional beneficial effects on platelet
activation and pulmonary vascular remodeling.
Sildenafil, a selective PDE5 inhibitor, significantly decreases PVR
within 3 months of starting therapy in patients deemed inoperable or
with residual PH after PEA surgery. This initial improvement translates
into significantly improved hemodynamics (including cardiac index),
BNP level, 6-min walk distance, and symptom scores with 12 months
of therapy, possibly suggesting that sildenafil has disease-modifying
effects on the pulmonary vasculature [21].
Standard dosage Sildenafil: oral administration starting at 20 mg three times daily.
Contraindications Concomitant use of nitrates (eg, nitroglycerin); hypersensitivity [24].
Main drug interactions Contraindicated: erythrityl tetranitrate, isosorbide di- or mononitrate,
nitroglycerin, and pentaerythritol tetranitrate. Major interaction: dihydroco-
deine and ritonavir [24].
Main side effects Flushing (10%), dyspepsia (up to 30%), headache (16–46%), visual
disturbance (3–11%) [21, 24].
Prostanoid therapy
Prostanoids have several important effects on the vasculature; they are
potent vasodilators that also inhibit vascular smooth muscle prolifera-
tion and platelet aggregation.
Continuous IV administration of epoprostenol via infusion pump to
patients with PVR greater than 1200 dynes·s·cm
−5 before PEA surgery
may significantly increase preoperative cardiac output and reduces PVR
[10, 22]. These effects translate into reduced right ventricular strain, as
measured by decreased preoperative BNP levels [22].
Open-label trials have shown that continuous subcutaneous admin-
istration of treprostinil improves hemodynamics, functional capacity,
and survivability in patients with inoperable CTEPH [18]. An inhaled
prostanoid, iloprost, also has been studied with variable results in
CTEPH patients [19, 23]. One small study demonstrated improved
pulmonary hemodynamics with acute administration of inhaled iloprost
in 20 CTEPH patients (14 inoperable), suggesting a component of
pulmonary vasoreactivity in these patients. However, sustained benefit
with this therapy was not examined [19].
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min to tolerance with a continuous infusion pump [22]. Treprostinil: sub-
cutaneous administration beginning at 2 ng/kg/min, increasing to tolerance
with a continuous infusion pump. The infusion site should be changed
about every 28 days [18]. Continuous IV formulations also are available.
Iloprost: 5-μg inhalation via nebulizer up to six times a day [19].
Contraindications Severe left ventricular systolic dysfunction, hypersensitivity, and pulmonary
edema [24].
Main drug interactions Major interaction: citalopram, clovoxamine, desvenlafaxine, duloxetine,
escitalopram, femoxetine, flesinoxan, fluoxetine, fluvoxamine, milnacipran,
nefazodone, paroxetine, sertraline, venlafaxine, and zimeldine [24].
Main side effects Flushing (up to 60%), jaw pain (54–75%), headaches (46–83%), epigastric
discomfort (up to 30%), loose stools (up to 50%), cough (with iloprost; up
to 39%), and bronchospasm (with iloprost) [22, 24].
Future directions
& Without surgical intervention, the prognosis for CTEPH patients
previously was observed to be poor [1•]. However, preliminary
reports suggesting hemodynamic and functional benefit from the use
of PH-specific pharmacotherapy in CTEPH patients who are not
surgical candidates have been encouraging, with evidence of
improved quality of life and survivorship in this patient group [25•].
Well-powered, randomized, placebo-controlled trials are needed to
evaluate PH pharmacotherapy in these patients, and as in PAH,
investigation of combination therapy likely is on the horizon.
Interventional procedures
& The routine placement of inferior vena cava filters in patients with
CTEPH is not a universally accepted practice. The proposed benefit
is to reduce the risk of perioperative and/or recurrent pulmonary
embolism in patients with diagnosed CTEPH. At the University of
California, San Diego (UCSD), inferior vena cava filter placement, in
addition to lifelong anticoagulation, has resulted in recurrent, oper-
able CTEPH in fewer than 1% of patients who have undergone
thromboendarterectomy surgery.
Surgery
& Pulmonary thromboendarterectomy, or what is increasingly referred
to as pulmonary endarterectomy surgery, has become the preferred
treatment for selected patients with CTEPH. Often, it is permanently
curative, as long as patients remain on lifelong anticoagulation,
and may result in a substantial improvement in cardiopulmonary
hemodynamics [8, 12, 26–28]. Significant improvements in
New York Heart Association functional class, dyspnea scores, gas
exchange/exercise capacity, and long-term survival have been
reported [25•, 29–31].
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& Important determinants of surgical candidacy for PEA are 1) the
presence of chronic organized thrombi involving the main, lobar,
and/or proximal segmental pulmonary arteries; 2) hemodynamic
impairment proportional to the anatomically evident disease; and 3)
the lack of other significant comorbid conditions that would con-
traindicate surgery [1•, 26]. Although patients with PVR greater than
1000 dynes·s·cm
−5 have increased perioperative mortality [4, 27],
referral to centers specialized in surgical treatment of CTEPH should
still be pursued in a timely manner. In these cases, preoperative
pharmacologic treatment to reduce PVR should be considered by the
medical–surgical endarterectomy team [26].
PEA surgery
& The management of CTEPH patients involves a multidisciplinary team
of surgeons, intensivists, pulmonologists, and other specialists who aid
in determining surgical candidacy and caring for the patient in the
perioperative setting. The surgery involves a median sternotomy
followed by the initiation of cardiopulmonary bypass. The patient is
cooled to the point of hypothermia; periods of intermittent circulatory
arrest allow adequate visualization of the pulmonary vasculature so
consecutive bilateral thromboendarterectomies can be performed [4].
PEA involves careful circumferential dissection of intraluminal
fibrinous material away from the arterial intima [4, 12]. After the
specimens are removed, the patient is warmed and the surgical sites are
sutured closed. Occasionally, a pericardial patch may be required to
close the pulmonary artery and restore its original dimensions.
Postoperative complications
& Although not inclusive, the list of common post-PEA complications is
similar to that of other open chest procedures and occurs at a similar
frequency: mediastinal hemorrhage, ventilator-associated pneumonia,
wound infections, atrial arrhythmias, delirium, and phrenic nerve
injury [8, 27]. For patients with antiphospholipid syndrome, as well as
CTEPH patients undergoing an endarterectomy of a main pulmonary
artery, early postoperative rethrombosis is of particular concern. The
experience at UCSD has resulted in the practice of therapeutic
anticoagulation within hours following the endarterectomy. Late
development (1–3 weeks postoperative) of an inflammatory pericar-
ditis occasionally may result in hemodynamic compromise and
requires percutaneous or surgical drainage. Relatively unique to this
patient population is the risk of postendarterectomy reperfusion lung
injury(RPLI),anacutehigh-permeability,inflammatorycondition that
may develop within the first 24 h of surgery and is associated with in-
creased oxygen and ventilator requirements. Postendarterectomy RPLI
can range from mild to severe acute lung injury (occasionally
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[1, 8, 27]. RPLI usually is treated with supportive care, but in severe
cases, inhaled nitric oxide and even extracorporeal life support may be
required [32]. Another postoperative difficulty is residual PH (defined
as postsurgical PVR9500 dynes·s·cm
−5) despite PEA surgery, which is
reported in 10–15% of patients [27, 33]. Although the presence of PH
after PEA does not typically mean there has been no hemodynamic
benefit from surgery, the presence of severe PH and right ventricular
failure postoperatively is associated with a much greater mortality risk.
Inananalysisof500patientswhounderwentPEA,17ofthe22patients
who died exhibited residual high pulmonary pressures [4].
Mortality
& With improvements in surgical technique, increased experience with
this patient population, and a multidisciplinary approach to perio-
perative care, operative mortality has been reduced to 4–7% at select
centers of excellence [4, 26]. Because the early mortality statistics
were as high as 17–23% [4, 26], it is imperative to refer CTEPH
patients to centers with considerable experience in the medical and
surgical management of this disease.
Other considerations
& In patients with risk factors for coronary atherosclerosis, coronary
angiography is recommended before surgery to determine whether
cardiac artery bypass grafting should also be performed at the time of
PEA. Valve repair or replacement, if required, also may be done during
thromboendarterectomy [34]. Although tricuspid regurgitation is
common in CTEPH patients, postoperative remodeling of the heart
following relief of high pulmonary pressures may result in renewed
tricuspidvalvecompetence[4].Therefore,tricuspidvalverepairrarelyis
required and is performed only in patients with a severely damaged
valve. Lastly, if there is evidence of improvement in the pulmonary
hemodynamics as the organized thrombi are removed, surgical closure
of a patent foramen ovale may be performed.
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